Paid Clinical Trials Paid Clinical Trials > Browse Categories > Mental Health Disorders > Cognitive Disorders (Delirium, Dementia) > Pick's Disease

Pick's Disease

Pick's Disease

All Categories Mental Health Disorders » Cognitive Disorders (Delirium, Dementia) » Pick's Disease


  • Human Placental-Derived Stem Cell Transplantation

    Conditions:   Mucopolysaccharidosis I;   Mucopolysaccharidosis VI;   Adrenoleukodystrophy;   Niemann-Pick Disease;   Metachromatic Leukodystrophy;   Wolman Disease;   Krabbe's Disease;   Gaucher's Disease;   Fucosidosis;   Batten Disease;   Severe Aplastic Anemia;   Diamond-Blackfan Anemia;   Amegakaryocytic Thrombocytopenia;   Myelodysplastic Syndrome;   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia
    Intervention:   Drug: Human Placental Derived Stem Cell
    Sponsors:   New York Medical College;   New York Medical College
    Not yet recruiting - verified April 2012
  • Effect of Feedback and Practice on Probabilistic Decision Making in Attention Deficit and Hyperactivity Disorder

    Condition:   ADHD
    Intervention:   Behavioral: probabilistic choice
    Sponsors:   Shaare Zedek Medical Center;   Shaare Zedek Medical Center
    Not yet recruiting - verified April 2012
  • A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

    Conditions:   Primary Cutaneous Anaplastic Large Cell Lymphoma,;   Mycosis Fungoides
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Methotrexate or Bexarotene
    Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.;   Seattle Genetics, Inc.
    Recruiting - verified May 2012
  • A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: inotuzumab ozogamicin;   Drug: FLAG (fludarabine, cytarabine and G-CSF);   Drug: HIDAC (high dose cytarabine);   Drug: cytarabine and mitoxantrone
    Sponsors:   Pfizer;   Pfizer;   Union Chimique Belge
    Not yet recruiting - verified May 2012
  • OxCKD1 -Empowering Healthy Lifestyle Choices in Chronic Kidney Disease

    Condition:   Chronic Kidney Disease
    Intervention:   Other: OxSalt care bundle
    Sponsors:   University of Oxford;   University of Oxford;   British Renal Society
    Not yet recruiting - verified May 2012
  • Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

    Conditions:   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
    Interventions:   Biological: talactoferrin;   Other: laboratory biomarker analysis
    Sponsors:   Stanford University;   Stanford University;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Barriers to Peritoneal Dialysis Selection

    Condition:   Chronic Kidney Disease
    Intervention:  
    Sponsors:   MetroHealth Medical Center;   Suma Prakash, MD
    Not yet recruiting - verified January 2012
  • Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

    Conditions:   Alzheimer's Disease;   Mild Cognitive Impairment;   Vascular Dementia;   Fronto-temporal Dementia;   Primary Progressive Aphasia;   Parkinson' Disease Dementia;   Mixed Dementia
    Intervention:  
    Sponsors:   Exonhit;   Exonhit
    Recruiting - verified December 2011
  • Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

    Conditions:   Amyotrophic Lateral Sclerosis;   Frontotemporal Dementia;   PLS;   Motor Neuron Disease;   Lou Gehrigs Disease;   Familial Disease;   Amyotrophic Lateral Sclerosis, Sporadic
    Intervention:  
    Sponsors:   University of Massachusetts, Worcester;   University of Massachusetts, Worcester;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting - verified May 2012
  • The BEACON Study (Breast Cancer Outcomes With NKTR-102)

    Conditions:   Locally Recurrent Breast Cancer;   Metastatic Breast Cancer
    Interventions:   Drug: NKTR-102;   Drug: Treatment of Physician's Choice (TPC)
    Sponsors:   Nektar Therapeutics;   Nektar Therapeutics
    Recruiting - verified April 2012
  • Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

    Conditions:   Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
    Interventions:   Drug: Alisertib;   Drug: Pralatrexate;   Drug: Romidepsin;   Drug: Gemcitabine
    Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2012
  • Customized Choice of Oral P2Y12 Receptor Blocker

    Conditions:   Acute Coronary Syndrome;   Coronary Angioplasty
    Interventions:   Drug: Oral P2Y12 receptor blocker;   Drug: Customized choice for the oral P2Y12 receptor blocker
    Sponsors:   Italian Society of Invasive Cardiology;   Italian Society of Invasive Cardiology;   Eustrategy
    Recruiting - verified January 2012
  • A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

    Conditions:   CD27 Expressing B-cell Malignancies;   CD27 Expressing Solid Tumors;   Chronic Lymphocytic Leukemia;   Burkett's Lymphoma;   Mantle Cell Lymphoma;   Primary Lymphoma of the Central Nervous System;   Marginal Zone B Cell Lymphoma;   Solid Tumor;   Metastatic Melanoma;   Renal (Clear) Cell Carcinoma;   Hormone-refractory Prostate Adenocarcinoma;   Ovarian Cancer;   Colorectal Adenocarcinoma;   Non-small Cell Lung Cancer
    Intervention:   Drug: CDX-1127
    Sponsors:   Celldex Therapeutics;   Celldex Therapeutics
    Recruiting - verified May 2012
  • A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

    Condition:   Non-Small Cell Lung Cancer (NSCLC)
    Interventions:   Drug: Eribulin;   Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
    Sponsors:   Eisai Inc.;   Eisai Inc.
    Recruiting - verified April 2012
  • Increasing Engagement in PTSD Treatment Through Patient Education and Patient Choice

    Condition:   Posttraumatic Stress Disorder (PTSD)
    Interventions:   Behavioral: Informed decision making;   Behavioral: Placebo session
    Sponsors:   Michael Debakey Veterans Affairs Medical Center;   Michael Debakey Veterans Affairs Medical Center;   South Central VA Mental Illness Research, Education & Clinical Center
    Not yet recruiting - verified October 2011
  • Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

    Conditions:   Breast Neoplasms;   Neoplasm Metastasis
    Interventions:   Drug: afatinib;   Drug: afatinib;   Drug: Vinorelbine;   Drug: Investigator's choice of treatment
    Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
    Recruiting - verified May 2012
  • Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized

    Condition:   Alzheimer's Disease
    Intervention:  
    Sponsors:   Rambam Health Care Campus;   Rambam Health Care Campus
    Not yet recruiting - verified July 2011
  • Safety Study of Intranasal Oxytocin in Frontotemporal Dementia

    Condition:   Frontotemporal Dementia
    Interventions:   Drug: oxytocin;   Drug: Saline Nasal Mist
    Sponsors:   Lawson Health Research Institute;   Lawson Health Research Institute;   The Consortium of Canadian Centres for Clinical Cognitive Research (C5R)
    Recruiting - verified June 2011
  • A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

    Condition:   Breast Cancer
    Interventions:   Drug: trastuzumab emtansine;   Drug: anti-cancer therapy
    Sponsors:   Genentech;   Genentech
    Recruiting - verified March 2012
  • Trial in Children With Growth Failure Due to Early Onset Lysosomal Acid Lipase (LAL) Deficiency/Wolman Disease

    Conditions:   Lysosomal Acid Lipase Deficiency;   Wolman Disease
    Intervention:   Drug: SBC-102
    Sponsors:   Synageva BioPharma Corp.;   Synageva BioPharma Corp.
    Recruiting - verified October 2011
  • Nitrates and Bone Turnover: Trial to Select the Best Nitrate Preparation

    Condition:   Osteoporosis
    Interventions:   Drug: Nitrates;   Other: Placebo
    Sponsors:   University of Toronto;   University of Toronto;   The Physicians' Services Incorporated Foundation;   California Pacific Medical Center;   Sunnybrook Health Sciences Centre
    Not yet recruiting - verified June 2011
  • Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally

    Conditions:   Pain;   Sickle Cell Disease
    Interventions:   Drug: Morphine;   Drug: Nubain
    Sponsors:   Children's Healthcare of Atlanta;   Children's Healthcare of Atlanta;   Atlanta Clinical and Translational Science Institute
    Recruiting - verified September 2009
  • Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Open Label Drug Certolizumab Pegol (CZP);   Procedure: Arthroscopic synovial tissue biopsy
    Sponsors:   Arthritis Treatment Center, Maryland;   Nathan Wei, MD, FACP, FACR:;   University of California, San Diego
    Recruiting - verified September 2011
  • Assessment of Social-emotional Functioning in Neurological Diseases

    Conditions:   Alzheimer Disease;   Stroke;   Parkinson's Disease;   Lewy Body Dementia;   Huntington Disease
    Intervention:   Behavioral: Computerized tests and Electrophysiological measurements
    Sponsors:   Centre Hospitalier Universitaire, Amiens;   Centre Hospitalier Universitaire, Amiens
    Recruiting - verified April 2011
  • Biomarker for Niemann Pick Type C Disease

    Conditions:   Niemann-Pick Disease;   Niemann-Pick Disease, Type C
    Intervention:  
    Sponsors:   University of Rostock;   University of Rostock
    Recruiting - verified March 2011
  • Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia

    Conditions:   Leukaemia, Lymphocytic, Chronic;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Ofatumumab;   Drug: Physicians' Choice
    Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
    Recruiting - verified May 2012
  • Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

    Conditions:   Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
    Interventions:   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Genetic: gene expression analysis;   Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: aromatase inhibition therapy
    Sponsors:   Virginia Commonwealth University;   Virginia Commonwealth University;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.

    Condition:   Indolent B-cell NHL
    Intervention:   Drug: Bendamustine IV
    Sponsors:   Mundipharma Research Limited;   Mundipharma Research Limited
    Recruiting - verified February 2012
  • Making Calories Count: Information Format and Food Choice

    Condition:   Obesity
    Interventions:   Behavioral: Provide menu with visual cue and calorie information;   Behavioral: Provide menu with visual cue but no calorie information;   Behavioral: Provide menu with no visual cue but with calorie information;   Behavioral: Provide menu with no visual cue and no calorie information
    Sponsors:   University of Pennsylvania;   University of Pennsylvania;   National Institute on Aging (NIA)
    Recruiting - verified January 2012
  • Study of Options for Second-Line Effective Combination Therapy (SELECT)

    Condition:   HIV-1 Infection
    Interventions:   Drug: Lopinavir/ritonavir;   Drug: Lopinavir/ritonavir;   Drug: Raltegravir;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Abacavir/lamivudine/zidovudine;   Drug: Abacavir/lamivudine;   Drug: Lamivudine/zidovudine;   Drug: Abacavir;   Drug: Zidovudine;   Drug: Lamivudine
    Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting - verified October 2011
  • A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

    Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, B-cell;   Lymphoma, B-cell, Diffuse
    Interventions:   Drug: Inotuzumab ozogamicin;   Drug: Rituximab;   Drug: rituximab + gemcitabine;   Drug: rituximab +bendamustine
    Sponsors:   Pfizer;   Pfizer;   UCB, Inc.
    Recruiting - verified April 2012
  • Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Drug: hydroxychloroquine;   Drug: imatinib mesylate;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   University of Glasgow;   Lynn McMahon;   Medical Research Council;   CRUK Trials unit Glasgow
    Recruiting - verified November 2011
  • Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer

    Condition:   Breast Cancer
    Intervention:   Radiation: multiple beams utilizing either intensity-modulated or 3D-conformal techniques
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified April 2012
  • Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases

    Conditions:   Occupational Accidents;   Incubation Period, Infectious Disese
    Intervention:  
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified June 2011
  • Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls

    Conditions:   Frontotemporal Dementia;   Frontotemporal Degeneration;   Alzheimer's Disease;   Social Behavior
    Intervention:  
    Sponsors:   University of California, Los Angeles;   University of California, Los Angeles;   National Institute on Aging (NIA)
    Recruiting - verified October 2011
  • Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B Cell Lymphoma

    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Drug: Lenalidomide;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Rituximab;   Drug: Etoposide
    Sponsors:   Celgene Corporation;   Celgene Corporation
    Recruiting - verified September 2010
  • MIBG Scintigraphy as a Tool for Selecting Patients Requiring Implantable Cardioverter Defibrillator (ICD)

    Conditions:   Heart Failure;   Sudden Death
    Intervention:   Radiation: MIBG for diagnostic purpose
    Sponsors:   Assistance Publique - Hôpitaux de Paris;   Assistance Publique - Hôpitaux de Paris
    Recruiting - verified April 2010
  • Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas

    Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Burkitt Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Grade 1 Follicular Lymphoma;   Stage II Grade 2 Follicular Lymphoma;   Stage II Grade 3 Follicular Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: bendamustine hydrochloride;   Drug: carboplatin;   Biological: rituximab;   Drug: etoposide
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC)

    Condition:   Non-small Cell Lung Cancer
    Intervention:  
    Sponsors:   Washington University School of Medicine;   Jennifer Bell;   University of Virginia;   University of North Carolina;   Emory University
    Recruiting - verified October 2011
  • Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

    Conditions:   Breast Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
    Interventions:   Other: questionnaire administration;   Procedure: evaluation of cancer risk factors;   Procedure: quality-of-life assessment;   Procedure: study of high risk factors
    Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Choosing Healthy Options in College Environments and Settings

    Condition:   Obesity
    Interventions:   Behavioral: Web-Only Curriculum;   Behavioral: Face-to-Face, In-Person Class;   Behavioral: Web-Enhanced
    Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Minnesota - Clinical and Translational Science Institute;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified August 2011
  • Pilot Study Using Molecular Profiling to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer.

    Condition:   Metastatic Breast Cancer
    Intervention:   Drug: (will be assigned based on molecular profile and RPMA)
    Sponsors:   TGen Drug Development Services;   TGen Drug Development Services;   SideOut Foundation
    Recruiting - verified January 2012
  • A Study Of PF-04449913 In Select Hematologic Malignancies

    Condition:   Hematologic Malignancies
    Intervention:   Drug: PF-04449913
    Sponsors:   Pfizer;   Pfizer
    Recruiting - verified May 2012
  • Non-Treatment Study of Factors Affecting Cocaine Drug Choice

    Conditions:   Cocaine Abuse or Dependence;   Cocaine Related Disorders
    Intervention:  
    Sponsors:   Wayne State University;   Wayne State University;   National Institute on Drug Abuse (NIDA)
    Recruiting - verified October 2011
  • Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer

    Condition:   Non Small Cell Lung Cancer
    Interventions:   Drug: Pemetrexed;   Drug: Carboplatin
    Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Eli Lilly and Company
    Recruiting - verified March 2012
  • A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

    Conditions:   Mantle Cell Lymphoma;   Relapsed or Refractory Mantle Cell Lymphoma
    Interventions:   Drug: Lenalidomide;   Drug: Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
    Sponsors:   Celgene Corporation;   Celgene Corporation
    Recruiting - verified May 2012
  • Genetics of ALS: Identification of Genes With Roles in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS) and Amyotrophic Lateral Sclerosis (ALS) With Frontotemporal Dementia

    Conditions:   Amyotrophic Lateral Sclerosis;   Familial Amyotrophic Lateral Sclerosis;   Amyotrophic Lateral Sclerosis With Frontotemporal Dementia;   Lou Gehrig's Disease;   Motor Neuron Disease;   Primary Lateral Sclerosis
    Intervention:   Other: Genetic study of ALS families
    Sponsors:   Northwestern University;   Northwestern University
    Recruiting - verified July 2011
  • A Multicenter Prospective Study of Quality of Life in Adult Scoliosis

    Condition:   Scoliosis
    Interventions:   Procedure: Surgical intervention;   Other: Non operative intervention
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   Northwestern University;   New York University;   University of Virginia;   University of Louisville;   Maryland Spine Center;   Hospital for Special Surgery, New York;   University Health Network, Toronto;   Hopital du Sacre', Montreal University;   Dartmouth-Hitchcock Medical Center
    Recruiting - verified April 2012
  • Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells

    Conditions:   Sickle Cell Disease;   Thalassemia;   Anemia;   Granuloma;   Wiskott-Aldrich Syndrome;   Chediak Higashi Syndrome;   Osteopetrosis;   Neutropenia;   Thrombocytopenia;   Hurler Disease;   Niemann-Pick Disease;   Fucosidosis
    Intervention:   Procedure: Hematopoietic stem cell transplantation
    Sponsors:   Children's Hospital Los Angeles;   Children's Hospital Los Angeles
    Recruiting - verified June 2011
  • Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics

    Condition:   Major Depressive Disorder
    Interventions:   Drug: Antidepressants through Texas Medication Algorithm (TMA);   Behavioral: Brief Interpersonal Psychotherapy (IPT-B)
    Sponsors:   New York State Psychiatric Institute;   New York State Psychiatric Institute;   National Institute of Mental Health (NIMH)
    Recruiting - verified February 2012
  • Effects of Stress and Other Factors on Opiate Drug Choice.

    Conditions:   Heroin Dependence;   Opioid-Related Disorders
    Intervention:  
    Sponsors:   Wayne State University;   Wayne State University;   National Institute on Drug Abuse (NIDA)
    Recruiting - verified October 2011
  • Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

    Condition:   Non Small Cell Lung Cancer
    Interventions:   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Vinorelbine;   Drug: Paclitaxel;   Drug: Carboplatin;   Radiation: Thoracic Radiation Therapy (TRT);   Radiation: Thoracic Radiation Therapy (TRT)
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified May 2012
  • PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia

    Conditions:   Frontotemporal Lobar Degeneration;   Dementia
    Intervention:  
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Mental Health (NIMH)
    Recruiting - verified August 2011
  • Effects of Tolcapone on Frontotemporal Dementia

    Condition:   Frontotemporal Lobar Degeneration
    Intervention:   Drug: Tolcapone
    Sponsors:   Columbia University;   Columbia University;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting - verified October 2011
  • Language in Primary Progressive Aphasia

    Condition:   Primary Progressive Aphasia
    Intervention:  
    Sponsors:   Northwestern University;   Northwestern University;   National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting - verified April 2012
  • Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)

    Condition:   Non Small Cell Lung Cancer
    Intervention:   Drug: Erlotinib
    Sponsors:   University Health Network, Toronto;   University Health Network, Toronto;   Hoffmann-La Roche
    Recruiting - verified December 2011
  • CHOICE: Carotid Stenting For High Surgical-Risk Patients

    Condition:   Carotid Artery Disease
    Intervention:   Device: RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6
    Sponsors:   Abbott Vascular;   Abbott Vascular
    Recruiting - verified January 2012
  • Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C

    Condition:   Neimann-Pick Disease
    Intervention:  
    Sponsors:   National Institutes of Health Clinical Center (CC);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified November 2011

Main Menu
Clinical Trial Categories
Clinical Trial Locations